Related Experiment Video
Updated: Aug 29, 2026
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
Technical standards and guidelines for Huntington disease testing
Nicholas T Potter1, Elaine B Spector, Thomas W Prior
1Molecular Subcommittee of the Laboratory Quality Assurance Committee, Huntington Disease Molecular Working Group, and Laboratory Quality Assurance Committee, Bethesda, Maryland, USA.
Insights
The American College of Medical Genetics and Genomics (ACMG) provides updated guidelines for Huntington Disease (HD) testing. These guidelines offer flexibility for laboratory directors using various molecular genetics platforms.
Area of Science:
- Molecular Genetics
- Clinical Laboratory Science
Background:
- The ACMG Laboratory Quality Assurance (QA) Committee aims to establish standards for clinical genetics laboratories.
- The Huntington Disease (HD) Working Group, under the Molecular Subcommittee, developed these guidelines.
Purpose of the Study:
- To provide helpful, non-restrictive guidelines for Huntington Disease (HD) testing.
- To offer technique-specific guidance for commonly used HD testing technologies.
Main Methods:
- Development of guidelines by the HD Working Group.
- Inclusion of technique-specific information for current commercial HD testing platforms.
Main Results:
- Guidelines are intended as a helpful resource, not a rigid mandate.
- Laboratory directors retain flexibility in choosing testing platforms and strategies.
Conclusions:
- These guidelines support quality assurance in molecular genetics testing for HD.
- The document acknowledges that technologies evolve and may necessitate future revisions.
Abstract:
One mission of the ACMG Laboratory Quality Assurance (QA) Committee is to develop standards and guidelines for clinical genetics laboratories, including cytogenetics, biochemical, and molecular genetics specialties. This document was developed under the auspices of the Molecular Subcommittee of the Laboratory QA Committee by the Huntington Disease (HD) Working Group. These guidelines are not to be interpreted as restrictive or the only approach but to provide a helpful guide. Certainly, appropriately trained and credentialed laboratory directors have flexibility to utilize various testing platforms and design testing strategies with considerable latitude. We felt that it was essential to include technique-specific guidelines of several current technologies commonly used in laboratories providing HD testing, because the technologies discussed are available commercially and are widely utilized. We take the view that these technologies may change, and thus this document may change with future review.
